At NovoBliss Research®, our strategic roadmap is guided by innovation, scalability, and scientific integrity. By December 2026, we aim to establish a joint venture with an advanced In-Vitro laboratory, enabling us to expand our research capabilities in Pharmaceuticals, Nutraceuticals, dermatological, and cosmeceutical domains. Concurrently, we plan to transition to a cost-efficient Electronic Data Capture (EDC) system, enhancing study efficiency, data accuracy, and compliance with global regulatory standards. These initiatives will allow NovoBliss to deliver faster, smarter, and more reliable clinical insights to our domestic and global partners.

Looking ahead, NovoBliss is set to pioneer market surveillance initiatives by launching a dedicated program for testing counterfeit or substandard cosmetic products by the year 2027, reinforcing our commitment to consumer safety and product authenticity. By 2028, we envision the establishment of international offices across the U.S., South Korea, and Europe, strengthening our global presence and collaborative research network. Through these forward-looking milestones, NovoBliss Research continues to advance its mission bridging science, compliance, and innovation to drive the next generation of clinical excellence.